30-Jul-2026
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Globe Newswire (Wed, 29-Jul 8:00 AM ET)
Globe Newswire (Wed, 15-Jul 8:00 AM ET)
Globe Newswire (Wed, 8-Jul 8:00 AM ET)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 5-Jun 8:00 AM ET)
Globe Newswire (Tue, 2-Jun 8:00 AM ET)
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Mon, 1-Jun 4:10 PM ET)
Globe Newswire (Fri, 15-May 8:00 AM ET)
Globe Newswire (Wed, 13-May 8:00 AM ET)
UroGen Pharma Rallies as Investors Eye Trio of High-Profile Conferences in May
Market Chameleon (Fri, 8-May 7:21 AM ET)
UroGen Pharma to Present at Upcoming Investor Conferences
Globe Newswire (Thu, 7-May 8:00 AM ET)
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Urogen Pharma Ltd. - trades on the NASDAQ stock market under the symbol URGN.
As of July 30, 2026, URGN stock price climbed to $41.09 with 398,472 million shares trading.
URGN has a beta of 1.62, meaning it tends to be more sensitive to market movements. URGN has a correlation of 0.11 to the broad based SPY ETF.
URGN has a market cap of $2.00 billion. This is considered a Mid Cap stock.
Last quarter Urogen Pharma Ltd. - reported $51 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.03.
In the last 3 years, URGN traded as high as $43.93 and as low as $3.42.
The top ETF exchange traded funds that URGN belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
URGN has outperformed the market in the last year with a price return of +117.4% while the SPY ETF gained +17.9%. URGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +76.0% and +3.2%, respectively, while the SPY returned +4.5% and -1.7%, respectively.
URGN support price is $39.07 and resistance is $41.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that URGN shares will trade within this expected range on the day.